Portola leads with $60M round

CompanyAmount/RoundLead InvestorsDescription
Portola Pharmaceuticals
South San Francisco
D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK

Most of the funding will be used to advance Portola's lead drug betrixaban.

Light Sciences Oncology
Bellevue, WA

The funding will be used to advance its work on light infusion therapies.

Dicerna Pharmaceuticals
Cambridge, MA
Abingworth, Oxford Bioscience Partners and Skyline Ventures

Dicerna Pharmaceuticals is an RNA interference company.

Portola leads with $60M round

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.